Conditions: Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Keywords: Ph+ CML, chronic myeloid leukemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to supportive measures, when they are switched to nilotinib (CTCAE grading system).

Detailed description:
Study was terminated by Novartis

Arms:
arm 1: Dosage was 300 mg BID daily taken orally without food.

Interventions: intervention 1: Nilotinib
Intervention descriptions: intervention 1: supplied in 150 mg capsules to be taken orally

Protocol document: